Oncotelic Therapeutics (OTCMKTS:OTLC) Issues Earnings Results

Oncotelic Therapeutics (OTCMKTS:OTLC) announced its quarterly earnings data on Wednesday. The company reported $0.59 earnings per share for the quarter, Zacks reports.

Oncotelic Therapeutics Stock Down 5.2%

Shares of OTCMKTS:OTLC traded down $0.00 during trading on Wednesday, hitting $0.03. 161,262 shares of the company’s stock were exchanged, compared to its average volume of 279,958. Oncotelic Therapeutics has a 1-year low of $0.02 and a 1-year high of $0.11. The firm has a 50-day moving average price of $0.04 and a two-hundred day moving average price of $0.07.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.